Analyst Price Targets — EDIT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 5, 2026 8:46 pm | — | Chardan Capital | $4.00 | $3.04 | TheFly | Editas Medicine price target raised to $4 from $3.50 at Chardan |
| March 9, 2026 8:22 pm | — | Robert W. Baird | $6.00 | $2.32 | StreetInsider | Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings |
| November 5, 2024 10:23 am | Gena Wang | Barclays | $5.00 | $3.12 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $5 at Barclays |
| October 23, 2024 6:36 am | Yanan Zhu | Wells Fargo | $9.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo |
| October 22, 2024 1:41 pm | Joel Beatty | Robert W. Baird | $10.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $10 at Baird |
| August 8, 2024 7:24 am | Joon Lee | Truist Financial | $12.00 | $4.24 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities |
| August 8, 2024 6:44 am | Greg Harrison | Bank of America Securities | $15.00 | $4.21 | StreetInsider | BofA Securities Upgrades Editas Medicine (EDIT) to Buy |
| May 30, 2024 6:02 am | Liisa Bayko | Evercore ISI | $7.00 | $5.10 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI |
| May 9, 2024 12:34 am | Matthew Harrison | Morgan Stanley | $7.00 | $5.04 | StreetInsider | Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight |
| September 28, 2023 4:38 pm | Dae Gon Ha | Stifel Nicolaus | $17.00 | $6.92 | StreetInsider | Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation' |
Latest News for EDIT
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu…
CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.